Shinobi Therapeutics
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
7-day free trial · no credit card
Verified contacts
29
available on Kipplo
LinkedIn employees
42
11 to 50 range
Open roles
—
no listings
Distinct roles
14
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 29 verified contacts at Shinobi Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
29 contacts with verified email or phone · masked until revealed.
- BI
Bhanu Iyer
VP Us Operations & HR · Other
EmailPhone - JC
Jay Chen
Senior Principal Scientist · Science
EmailPhone - MO
Mitsujiro Osawa
Director · General Business & Management
EmailPhone - YN
Yoshiki Nakamura
Associate Director · Research & Development
EmailPhone - PY
Phillip Yamaguchi
Manager, Operations · Operations
EmailPhone - SS
Shogo Saito
アソシエイトディレクター · Other
EmailPhone - AJ
Alan Jacks
Sr Manager, Business Development Lead · Other
EmailPhone - EM
Eiki Maeda
VP, Head of Cmc & Manufacturing · Other
EmailPhone - MO
Masashi Ochi
VP, Head of Program Leadership and Management · Other
EmailPhone
Showing 9 of 29 verified contacts
Top roles at Shinobi Therapeutics
14 distinct titles indexed · top 10 shown.
- 3director
- 2senior principal scientist
- 1- &
- 1- - ä ü
- 1associate director
- 1manager, operations
- 1research associate
- 1senior director
- 1sr manager, business development lead
- 1vp us operations & hr
- +4more titles
Sign up to unlock all 29 contacts at Shinobi Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 29 verified contacts at Shinobi Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.